



This press release may constitute a public disclosure of inside information by Kepler S.p.A. under Regulation (EU) 596/2014 and Commission Implementing Regulation (EU) 2016/1055.

Biofarma Group Announces Establishment of Additional Revolving Credit Facility

Milan, Italy – 8 November 2024 – The Biofarma Group, the largest global CDMO focused on nutraceuticals, controlled by Ardian together with the Scarpa and the Luhadia families, announces that on 8 November 2024 Kepler S.p.A. (the “Company”) established an additional facility (the “Additional Facility”) among, *inter alios*, the Company, Biofarma S.r.l. (“Biofarma”) and the lenders party thereto (the “Lenders”), under its existing Super Senior Revolving Credit Facility (“SSRCF”) Agreement, dated as of 16 March 2022 (as amended, supplemented and/or restated from time to time, including by the Additional Facility Notice, the “Facility Agreement”), among, *inter alios*, the Company, Biofarma, BNP Paribas, as agent, and the lenders from time to time parties thereto.

The Additional Facility provides for incremental revolving credit commitments, in the aggregate principal amount of €43.5 million, which are undrawn as of the date hereof. The establishment of the Additional Facility brings the total potentially-available facilities, including undrawn commitments under the SSRCF as well as existing commitments of certain institutional investors to purchase additional facilities, to over €200 million, and will further enhance the liquidity position of the Biofarma Group, allowing it to continue to execute its strategy and business plan and, in turn, deliver value to its stakeholders.

www.biofarmagroup.it

Forward Looking Statements

This press release may include “forward-looking statements” within the meaning of the securities laws of applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this press release, including, without limitation, those regarding the Biofarma Group’s intentions, beliefs or current expectations concerning, among other things, its strategy, plans, objectives, prospects, growth, goals and targets. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.